Hossam Kamli*, Gaffar S. Zaman*, Ahmad Shaikh*, Abdullah A. Mobarki†, Prasanna Rajagopalan*‡
Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558
Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors.
Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by 1
H NMR, 13C NMR, and mass spectroscopy. Virtual docking and molecular dynamic
simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program.
Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1
cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was… More >
Login
Register
